D. E. Shaw & Co., Inc. Xeris Biopharma Holdings, Inc. Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
A detailed history of D. E. Shaw & Co., Inc. transactions in Xeris Biopharma Holdings, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 3,052,372 shares of XERS stock, worth $14.8 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
3,052,372
Previous 1,363,452
123.87%
Holding current value
$14.8 Million
Previous $4.62 Million
262.55%
% of portfolio
0.02%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding XERS
# of Institutions
204Shares Held
84.7MCall Options Held
132KPut Options Held
69.4K-
Black Rock Inc. New York, NY10.3MShares$50.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.11MShares$39.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.29MShares$20.8 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.41MShares$16.5 Million0.0% of portfolio
-
State Street Corp Boston, MA3.33MShares$16.1 Million0.0% of portfolio
About Xeris Biopharma Holdings, Inc.
- Ticker XERS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 135,956,992
- Market Cap $659M
- Description
- Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, h...